Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 12957454

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Eur J Cancer
Publication date
2003 Sep
First author
Verweij J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Eur J Cancer. 2003 Sep;39(14):1976-7. doi: 10.1016/s0959-8049(03)00555-0.
    note
    Source null
    related pmid
    12957451
    relationship
    Comment in
  2. citation
    Eur J Cancer. 2004 Sep;40(14):2016-21. doi: 10.1016/j.ejca.2004.02.018.
    note
    Source null
    related pmid
    15341973
    relationship
    Comment in

Authors and identifiers

  1. name
    Verweij J
    type
    Author
  2. name
    van Oosterom A
    type
    Author
  3. name
    Blay JY
    type
    Author
  4. name
    Judson I
    type
    Author
  5. name
    Rodenhuis S
    type
    Author
  6. name
    van der Graaf W
    type
    Author
  7. name
    Radford J
    type
    Author
  8. name
    Le Cesne A
    type
    Author
  9. name
    Hogendoorn PC
    type
    Author
  10. name
    di Paola ED
    type
    Author
  11. name
    Brown M
    type
    Author
  12. name
    Nielsen OS
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Verweij J
    type
    Author
  2. name
    van Oosterom A
    type
    Author
  3. name
    Blay JY
    type
    Author
  4. name
    Judson I
    type
    Author
  5. name
    Rodenhuis S
    type
    Author
  6. name
    van der Graaf W
    type
    Author
  7. name
    Radford J
    type
    Author
  8. name
    Le Cesne A
    type
    Author
  9. name
    Hogendoorn PC
    type
    Author
  10. name
    di Paola ED
    type
    Author
  11. name
    Brown M
    type
    Author
  12. name
    Nielsen OS
    type
    Author
bibliography ids
  1. nci-bib-0113962b8460087b7cb58017
book metadata
content sha256
7500aea2e8fe24d6c64bf7023d2077f36c2cd24fcf953f688f78542e7690bdeb
document type
citation
dois
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:12957454
    immutable id
    pubmed:12957454@7500aea2e8fe24d6c64bf7023d2077f36c2cd24fcf953f688f78542e7690bdeb
    journal
    abbreviation
    Eur J Cancer
    issn electronic
    Source null
    issn print
    0959-8049
    issue
    14
    name
    European journal of cancer (Oxford, England : 1990)
    nlm unique id
    9005373
    pages
    2006-11
    volume
    39
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
    1. citation
      Eur J Cancer. 2003 Sep;39(14):1976-7. doi: 10.1016/s0959-8049(03)00555-0.
      note
      Source null
      related pmid
      12957451
      relationship
      Comment in
    2. citation
      Eur J Cancer. 2004 Sep;40(14):2016-21. doi: 10.1016/j.ejca.2004.02.018.
      note
      Source null
      related pmid
      15341973
      relationship
      Comment in
    outcomes validated
    false
    pmid
    12957454
    provenance
    batch id
    2d0158fe73b50bb1a4bf
    provider
    NCBI PubMed ESummary
    record sha256
    5a48526c5d3b6b5d38d6ecaa7fc5a29b5badc95d42cbf20a535616132a4ec4c2
    response sha256
    d46de44782d91ef4394e88a69f82b1ee22148e8c4cf1534eb36c80479345e70e
    retrieved at
    2026-09-09T23:45:50.935339+00:00
    publication date
    display
    2003 Sep
    precision
    month
    year
    2003
    publication types
    1. Clinical Trial
    2. Clinical Trial, Phase II
    3. Journal Article
    4. Multicenter Study
    record status
    PubMed - indexed for MEDLINE
    schema version
    1.0
    source url
    https://pubmed.ncbi.nlm.nih.gov/12957454/
    title
    Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    Preserved source evidence · Not medical advice